0000899243-21-039749.txt : 20211008
0000899243-21-039749.hdr.sgml : 20211008
20211008182941
ACCESSION NUMBER: 0000899243-21-039749
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211005
FILED AS OF DATE: 20211008
DATE AS OF CHANGE: 20211008
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON JOHN
CENTRAL INDEX KEY: 0001410781
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40880
FILM NUMBER: 211316300
MAIL ADDRESS:
STREET 1: DENDREON CORPORATION
STREET 2: 1301 2ND AVENUE
CITY: SEATTLE
STATE: WA
ZIP: 98101
FORMER NAME:
FORMER CONFORMED NAME: Johnson John H
DATE OF NAME CHANGE: 20070827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc.
CENTRAL INDEX KEY: 0001867096
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2021-10-05
2021-10-05
0
0001867096
Xeris Biopharma Holdings, Inc.
XERS
0001410781
JOHNSON JOHN
C/O XERIS BIOPHARMA HOLDINGS, INC.
180 N. LASALLE STREET, SUITE 1600
CHICAGO
IL
60601
1
0
0
0
Common Stock
2021-10-05
4
A
0
478312
A
478312
D
Stock Option (Right to Buy)
22.39
2021-10-05
4
A
0
10367
A
2025-10-16
Common Stock
10367
10367
D
Stock Option (Right to Buy)
7.02
2021-10-05
4
A
0
31360
A
2026-05-12
Common Stock
31360
31360
D
Stock Option (Right to Buy)
5.62
2021-10-05
4
A
0
31360
A
2027-05-11
Common Stock
31360
31360
D
Stock Option (Right to Buy)
9.89
2021-10-05
4
A
0
31360
A
2028-05-15
Common Stock
31360
31360
D
Stock Option (Right to Buy)
1.99
2021-10-05
4
A
0
215600
A
2029-11-14
Common Stock
215600
215600
D
Stock Option (Right to Buy)
2.43
2021-10-05
4
A
0
68600
A
2030-04-08
Common Stock
68600
68600
D
Stock Option (Right to Buy)
2.37
2021-10-05
4
A
0
19650
2.37
A
2031-10-05
Common Stock
19650
19650
D
On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis.
At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.
These options are fully vested as of the date hereof.
One third of these options shall vest in equal annual installments until the third anniversary of the date of grant.
/s/ Beth Hecht, as Attorney-in-Fact
2021-10-08